Limitations of low mol. wt anticancer drugs are short
tumor exposure times and toxicity to normal tissue.
Methotrexate (MTX) covalently linked to
human serum albumin (HSA) as a macromolecular carrier caused
tumor regressions concomitant with a favorable toxicity profile in a clinical phase I trial (Hartung et aL, Clin.
Cancer Res., 1999, 5, 753). We examined the uptake, intracellular degradation, metabolism and
thymidylate synthase (TS) inhibition of
MTX-HSA in the
T-cell leukemia line CCRF-CEM and the MTX transport resistant clone CCRF-CEM/MTX. The number of MTX molecules per
albumin molecule was determined by electrospray mass spectrometry. A loading ratio (LR) of approximately 1.4 mol MTX/
albumin revealed intact complexes with one and two MTX molecules/
albumin. In the complex with an LR of 5.7,
albumin with up to 16 MTX molecules was seen.
MTX-HSA was taken up by CCRF-CEM cells via endocytosis and cleaved by lysosomal
enzymes. Liberated MTX was a poor substrate of
folylpolyglutamate synthetase and was exported into the medium. TS was inhibited and cell survival was impaired by
MTX-HSA in a time- and concentration-dependent manner. CCRF-CEM/MTX cells exhibited a growth inhibition of 30-40% after
MTX-HSA treatment, but no TS inhibition. The alternative uptake route via endocytosis enables
MTX-HSA to overcome transport resistance to MTX.